SubsidieMeestersTo deliver the first medical treatment dedicated to patients with haemorrhagic stroke
NANOp2lysis develops O2L-001, a safe, effective thrombolytic agent for intracerebral hematoma treatment via a single injection, enhancing delivery and reducing side effects post-hemorrhagic stroke.
Projectdetails
Introduction
The NANOp2lysis platform is a deep-tech technology to protect active enzymes by a reversible precipitation and to produce solid-state nanoparticles. Such particles can then be loaded at high concentration into tailored carriers (with specific targeting / slow delivery characteristics).
O2L-001 Overview
O2L-001 (derived from NANOp2Lysis) is the first effective and safe treatment to remove intracerebral hematoma and reduce disability and death following acute hemorrhagic stroke (AHS). It has been tailored to be locally injected, after micro-invasive surgery, via a catheter at the core of the hematoma.
Gelation and Delivery
The in vivo gelation of the product at body temperature allows a local and slow delivery of our new thrombolytic agent, OptPA.
Key Characteristics of O2L-001
The main characteristics of O2L-001 are thus the following:
- EASY: Simplified model of administration (unique injection)
- EFFICIENT: Better thrombolytic effect on the best translational model (vs gold standard)
- SAFE: Reduced side effects (bleeding and neurotoxicity vs gold standard)
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 10.535.727 |
Tijdlijn
| Startdatum | 1-7-2022 |
| Einddatum | 30-6-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- Op2Lysispenvoerder
- OP2LYSIS DEVELOPMENT
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market. | EIC Accelerator | € 2.498.816 | 2024 | Details |
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models. | EIC Accelerator | € 2.499.999 | 2024 | Details |
EDV2209 – a Paradigm shift in the treatment of stroke.Edvince aims to revolutionize stroke treatment with its innovative drug EDV2209, enhancing cerebral blood flow to prevent brain damage from severe subarachnoid hemorrhage. | EIC Accelerator | € 2.500.000 | 2022 | Details |
BraiN20®: A paradigm shift in Acute Ischemic Stroke (AIS) patient managementBraiN20 is a non-invasive device that monitors brain viability in AIS patients to enhance EVT decision-making and improve treatment outcomes through real-time data. | EIC Accelerator | € 2.500.000 | 2023 | Details |
An innovative filtration system to improve the coagulation properties of plasma units to treat patients with massive bleedingPlasFree is developing ClearPlasma™, a filtration system that extracts plasminogen to improve haemorrhage treatment and reduce plasma unit requirements, aiming for clinical validation and global impact. | EIC Accelerator | € 1.279.184 | 2022 | Details |
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)
The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market.
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)
NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models.
EDV2209 – a Paradigm shift in the treatment of stroke.
Edvince aims to revolutionize stroke treatment with its innovative drug EDV2209, enhancing cerebral blood flow to prevent brain damage from severe subarachnoid hemorrhage.
BraiN20®: A paradigm shift in Acute Ischemic Stroke (AIS) patient management
BraiN20 is a non-invasive device that monitors brain viability in AIS patients to enhance EVT decision-making and improve treatment outcomes through real-time data.
An innovative filtration system to improve the coagulation properties of plasma units to treat patients with massive bleeding
PlasFree is developing ClearPlasma™, a filtration system that extracts plasminogen to improve haemorrhage treatment and reduce plasma unit requirements, aiming for clinical validation and global impact.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
An injectable and programmable drug-eluting embolic deviceThis project develops a novel biodegradable drug delivery platform for liver cancer treatment, utilizing a two-step method to enhance drug perfusion and reduce adverse effects before vessel blockage. | ERC Proof of... | € 150.000 | 2023 | Details |
Versatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders.POLYBRAINT aims to develop an innovative intranasal drug delivery platform to effectively transport biological agents across the blood-brain barrier for treating CNS disorders. | ERC Proof of... | € 150.000 | 2022 | Details |
STOPtheBLEED – Ontwikkeling van unieke combinatie van stollingsfactoren en gelatine particles om ernstige bloedingen veroorzaakt door trauma te stoppenSTOPtheBLEED ontwikkelt een innovatief hemostaseproduct voor het snel en effectief stoppen van ernstige bloedingen door trauma, gericht op gebruik door niet-medische hulpverleners. | Mkb-innovati... | € 335.944 | 2016 | Details |
4D Brain-Targeting Nanomedicines for Treating NeurodegenerationThis project aims to develop advanced 4D-brain-targeting nanoparticles using nanotechnology to effectively deliver treatments for neurodegenerative diseases across the blood-brain barrier. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Nanotechnology-enabled deep profiling of the blood and brain proteome at the intersection of neurodegeneration and neurooncologyNanoNeuroOmics aims to discover early blood biomarkers for Alzheimer's and Glioblastoma using nanotechnology and proteomics to bridge the gap between brain and blood molecular changes. | ERC Starting... | € 1.494.954 | 2025 | Details |
An injectable and programmable drug-eluting embolic device
This project develops a novel biodegradable drug delivery platform for liver cancer treatment, utilizing a two-step method to enhance drug perfusion and reduce adverse effects before vessel blockage.
Versatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders.
POLYBRAINT aims to develop an innovative intranasal drug delivery platform to effectively transport biological agents across the blood-brain barrier for treating CNS disorders.
STOPtheBLEED – Ontwikkeling van unieke combinatie van stollingsfactoren en gelatine particles om ernstige bloedingen veroorzaakt door trauma te stoppen
STOPtheBLEED ontwikkelt een innovatief hemostaseproduct voor het snel en effectief stoppen van ernstige bloedingen door trauma, gericht op gebruik door niet-medische hulpverleners.
4D Brain-Targeting Nanomedicines for Treating Neurodegeneration
This project aims to develop advanced 4D-brain-targeting nanoparticles using nanotechnology to effectively deliver treatments for neurodegenerative diseases across the blood-brain barrier.
Nanotechnology-enabled deep profiling of the blood and brain proteome at the intersection of neurodegeneration and neurooncology
NanoNeuroOmics aims to discover early blood biomarkers for Alzheimer's and Glioblastoma using nanotechnology and proteomics to bridge the gap between brain and blood molecular changes.